AstraZeneca has secured another approval for its cancer blockbuster IMFINZI (durvalumab), as the FDA has approved the PD-L1 inhibitor for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent chemotherapy and radiation.
This approval makes IMFINZI the first immunotherapy available for LS-SCLC, a highly aggressive cancer subtype with a post-diagnosis survival rate of 15% to 30%. Lung cancer is the primary cause of cancer-related deaths in both men and women, responsible for roughly 20% of all cancer fatalities.
Limited-stage SCLC, referring to stages I-III, is typically confined to one lung or one...
